Sponsored Links
| Three-Year Data From Phase 2 Trial Of Genzyme Gaucher Disease Oral Compound Suggest Sustained Or Further Improvement Across All Endpoints |
 |
 |
 |
| Medical News - Lymphology and Lymphedema | |||
|
Genzyme Corporation (NASDAQ: GENZ) announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint... Read more: Lymphology/Lymphedema News From Medical News Today
|